Molnupiravir: All you need to know about the oral anti-Covid pill

World’s first oral anti-Covid pill, Molnupiravir, has been approved by the UK and is likely to green light in India soon. It’s been hailed as a gamechanger in the fight against Covid-19.

Here’s all you need to know about the anti-Covid pill:

  • Approved for use in the UK, likely to get nod in India soon
  • First oral medicine in the world to be approved for use against Covid
  • Developed by the pharmaceutical companies Ridgeback Biotherapeutics and Merck, Sharp and Dohme
  • The antiviral drug molnupiravir was originally developed to treat the flu
  • Meant for adults at risk for progressing to severe Covid or hospitalisation
  • To be given to patients within 5 days of symptoms appearing
  • Will be given twice a day to patients recently diagnosed with Covid
  • Molnupiravir works by disrupting the virus’s reproduction.
  • Reduces the risk of hospitalisation or Covid death by 50%
  • Ineffective if it’s taken after the patient is hospitalised
  • The treatment can be given to both vaccinated and unvaccinated patients

Also Read/Watch: Britain clears Merck’s pill to treat Covid-19: here’s all you need to know about molnupiravir

Watch More Covid Video News and Latest Covid Updates on

Digital Editor